ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.098,09
-0,50%
S&P 500
5.277,51
0,80%
US Dollar vs BRL
5,2463
0,01%
Bitcoin
67.746,72
0,39%
Brent Oil
81,295
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Intrexon Corporation (XON)

  7. Intrexon Corporation (XON) Notícias

XON

Intrexon (XON)

Intrexon Corporation
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:XON
DataHoraFonteTítuloCódigoCompanhia
26/01/202118:05PR Newswire (US)Precigen Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional SharesNASDAQ:XONIntrexon Corporation
06/01/202110:05PR Newswire (US)Precigen to Present at the 39th Annual J.P. Morgan Healthcare ConferenceNASDAQ:XONIntrexon Corporation
09/11/202010:05PR Newswire (US)Precigen Reports Third Quarter 2020 and Year-to-Date Financial ResultsNASDAQ:XONIntrexon Corporation
02/11/202018:05PR Newswire (US)Precigen to Announce Third Quarter 2020 Financial Results on November 9th: Will host Pipeline and Data Update Call in Early D...NASDAQ:XONIntrexon Corporation
04/06/202017:24Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:XONIntrexon Corporation
04/06/202017:22Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XONIntrexon Corporation
19/05/202017:35Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XONIntrexon Corporation
11/05/202018:05Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:XONIntrexon Corporation
29/04/202007:25Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:XONIntrexon Corporation
02/03/202018:57Edgar (US Regulatory)Annual Report (10-k)NASDAQ:XONIntrexon Corporation
14/02/202016:32Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:XONIntrexon Corporation
11/02/202019:08Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:XONIntrexon Corporation
06/02/202018:25Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:XONIntrexon Corporation
04/02/202019:00Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:XONIntrexon Corporation
03/02/202009:30PR Newswire (US)Precigen Completes Series Of Transactions To Solidify Healthcare FocusNASDAQ:XONIntrexon Corporation
22/01/202008:38Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:XONIntrexon Corporation
09/01/202009:30PR Newswire (US)Triple-Gene Announces Presentation at Upcoming Biotech Showcase Investor ConferenceNASDAQ:XONIntrexon Corporation
06/01/202009:30PR Newswire (US)Precigen Receives FDA Orphan Drug Designation for PRGN-3006 UltraCAR-T™ in Patients with Acute Myeloid Leukemia (AML)NASDAQ:XONIntrexon Corporation
02/01/202012:33PR Newswire (US)Darling Ingredients Acquires 100% of EnviroFlightNASDAQ:XONIntrexon Corporation
02/01/202009:55PR Newswire (US)Intrexon To Achieve $175M Cash Goal, Appoints Helen Sabzevari, PhD, As New President And CEO And Will Change Name To Precigen...NASDAQ:XONIntrexon Corporation
18/11/201909:30PR Newswire (US)Triple-Gene Presented Preliminary Phase 1 Trial Data of Investigational Multigenic Therapeutic Candidate INXN‑4001 for Trea...NASDAQ:XONIntrexon Corporation
12/11/201909:30PR Newswire (US)Intrexon Reports Third Quarter 2019 Financial ResultsNASDAQ:XONIntrexon Corporation
07/11/201909:30PR Newswire (US)Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN‑4001, First Multigenic Investigational T...NASDAQ:XONIntrexon Corporation
04/11/201918:05PR Newswire (US)Intrexon to Announce Third Quarter Financial Results on November 12thNASDAQ:XONIntrexon Corporation
21/10/201920:37Dow Jones NewsOil Search Scales Back Production GuidanceNASDAQ:XONIntrexon Corporation
24/09/201905:00GlobeNewswire Inc.Next Green Wave Achieves Operational Milestones For Intrexon’s Botticelli™ Cannabis Plantlet ProductionNASDAQ:XONIntrexon Corporation
19/08/201908:30PR Newswire (US)ActoBio Therapeutics™ Receives IND Green Light for New Antigen-Specific Immunotherapy Study Aimed at Improving Celiac Patie...NASDAQ:XONIntrexon Corporation
12/08/201907:02Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:XONIntrexon Corporation
08/08/201918:15PR Newswire (US)Intrexon Reports Second Quarter and First Half 2019 Financial ResultsNASDAQ:XONIntrexon Corporation
05/08/201908:30PR Newswire (US)Precigen Announces First Patient Dosed in Phase 1 Study of PRGN-3005 UltraCAR-T™ in Patients with Advanced, Recurrent Plati...NASDAQ:XONIntrexon Corporation
 Apresentando as notícias mais relevantes sobre:NASDAQ:XON

Seu Histórico Recente

BIT
S29103
Societe Generale Effekten
BIT
I07914
Intesa Sanpaolo
BIT
P12AJ9
BNP PARIBAS ISSUANCE
LSE
59YH
Investec Bnk 27
COIN
LCSETH
LocalCoinSwap Cryptoshare
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados